OBJECTIVE: To estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking nevirapine (NVP)-containing regimens compared with HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP. METHODS: This analysis included HIV-infected pregnant women on ART from two multicenter, prospective cohorts: the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025. Multivariate Cox proportional hazards regression models were used to investigate the association between NVP use and hepatotoxicity. NVP use was dichotomized as use or no use and further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE) (grade 1-4) and severe LEE (grade 3-4). RESULTS: A total of 1229 women with ART use during pregnancy were studied, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naive. Twenty-nine women (13.3%) who received NVP developed any LEE and one (0.5%) developed severe LEE. Of the 1011 women on non-NVP regimens, 145 (14.3%) developed any LEE and 14 (1.4%) developed severe LEE. There were no maternal deaths. In univariate models, LEE was not significantly associated with CD4 cell count above 250 cells/mul or NVP use. In adjusted multivariate models, no significant increased risk of LEE (any or severe) in women taking NVP was detected as compared to those taking other ART regardless of prior exposure history. CONCLUSION: We did not observe an increased risk of hepatotoxicity among HIV-infected pregnant women on NVP versus other ART, including women who were ART naive.
OBJECTIVE: To estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking nevirapine (NVP)-containing regimens compared with HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP. METHODS: This analysis included HIV-infected pregnant women on ART from two multicenter, prospective cohorts: the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025. Multivariate Cox proportional hazards regression models were used to investigate the association between NVP use and hepatotoxicity. NVP use was dichotomized as use or no use and further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE) (grade 1-4) and severe LEE (grade 3-4). RESULTS: A total of 1229 women with ART use during pregnancy were studied, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naive. Twenty-nine women (13.3%) who received NVP developed any LEE and one (0.5%) developed severe LEE. Of the 1011 women on non-NVP regimens, 145 (14.3%) developed any LEE and 14 (1.4%) developed severe LEE. There were no maternal deaths. In univariate models, LEE was not significantly associated with CD4 cell count above 250 cells/mul or NVP use. In adjusted multivariate models, no significant increased risk of LEE (any or severe) in women taking NVP was detected as compared to those taking other ART regardless of prior exposure history. CONCLUSION: We did not observe an increased risk of hepatotoxicity among HIV-infected pregnant women on NVP versus other ART, including women who were ART naive.
Authors: F Lyons; S Hopkins; B Kelleher; A McGeary; G Sheehan; J Geoghegan; C Bergin; F M Mulcahy; P A McCormick Journal: HIV Med Date: 2006-05 Impact factor: 3.180
Authors: M C Marazzi; P Germano; G Liotta; G Guidotti; S Loureiro; A da Cruz Gomes; M C Valls Blazquez; P Narciso; C F Perno; S Mancinelli; L Palombi Journal: HIV Med Date: 2006-07 Impact factor: 3.180
Authors: Ian Sanne; Herve Mommeja-Marin; John Hinkle; John A Bartlett; Michael M Lederman; Gary Maartens; Charles Wakeford; Audrey Shaw; Joseph Quinn; Robert G Gish; Franck Rousseau Journal: J Infect Dis Date: 2005-02-10 Impact factor: 5.226
Authors: Esau Custódio João; Guilherme A Calvet; Jacqueline A Menezes; Marcos M D'Ippolito; Maria Letícia S Cruz; Luisa Andrea T Salgado; Haroldo J Matos Journal: Am J Obstet Gynecol Date: 2006-01 Impact factor: 8.661
Authors: Saju Joy; Ming Poi; Laura Hughes; Michael T Brady; Susan L Koletar; Michael F Para; Patty Fan-Havard Journal: Obstet Gynecol Date: 2005-11 Impact factor: 7.661
Authors: Annalise M Martin; David Nolan; Ian James; Paul Cameron; Jean Keller; Corey Moore; Elizabeth Phillips; Frank T Christiansen; Simon Mallal Journal: AIDS Date: 2005-01-03 Impact factor: 4.177
Authors: Jerry O Stern; Patrick A Robinson; James Love; Stephan Lanes; Michael S Imperiale; Douglas L Mayers Journal: J Acquir Immune Defic Syndr Date: 2003-09 Impact factor: 3.731
Authors: Jane Hitti; Lisa M Frenkel; Alice M Stek; Sharon A Nachman; David Baker; Adolfo Gonzalez-Garcia; Arthur Provisor; Edwin M Thorpe; Mary E Paul; Marc Foca; Jorge Gandia; Sharon Huang; Lee-Jen Wei; Laura M Stevens; D Heather Watts; James McNamara Journal: J Acquir Immune Defic Syndr Date: 2004-07-01 Impact factor: 3.731
Authors: Betty J Dong; Yu Zheng; Michael D Hughes; Adam Frymoyer; Davide Verotta; Patricia Lizak; Frederick Sawe; Judith S Currier; Shahin Lockman; Francesca T Aweeka Journal: AIDS Date: 2012-04-24 Impact factor: 4.177
Authors: Elizabeth G Livingston; Yanling Huo; Kunjal Patel; Susan B Brogly; Ruth Tuomala; Gwendolyn B Scott; Arlene Bardeguez; Alice Stek; Jennifer S Read Journal: Obstet Gynecol Date: 2010-08 Impact factor: 7.661
Authors: Timothy K Thomas; Rose Masaba; Craig B Borkowf; Richard Ndivo; Clement Zeh; Ambrose Misore; Juliana Otieno; Denise Jamieson; Michael C Thigpen; Marc Bulterys; Laurence Slutsker; Kevin M De Cock; Pauli N Amornkul; Alan E Greenberg; Mary Glenn Fowler Journal: PLoS Med Date: 2011-03-29 Impact factor: 11.069